ClinicalTrials.gg
Active, not recruitingNCT05739435Updated Jul 28, 2026

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

A Phase 2 interventional study of envudeucitinib in Plaque Psoriasis, sponsored by Alumis Inc. Active, not recruiting at 38 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Alumis Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
232nd of 673
165 · median 77
Started
2023
with 31 others
Phase 2
200 of 764
5 open now
Primary completion
2027-12
later than 48 of 85 live
Registered
677th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 232nd largest by enrollment of the 673 interventional ones that give a count, is one of 32 that started in 2023, is one of 200 in phase 2, reaches primary completion later than 48 of the 85 other live ones, and was the 677th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.

Read the detailed description

This study will consist of patients who have completed their participation in a previous plaque psoriasis study of ESK-001. Each patient will be assigned to receive ESK-001 at one of two open-label dose levels. Patients have the option to remain on study until ESK-001 is commercially available.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have completed a prior ESK-001 study
  • Men and Women must use highly effective methods of for the entirety of the study

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Received a prohibited concomitant medication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    envudeucitinib Dose Level 1

    envudeucitinib administered as an oral tablet

    Drug: envudeucitinib

  • Experimental
    envudeucitinib Dose Level 2

    envudeucitinib administered as an oral tablet

    Drug: envudeucitinib

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of long-term ESK-001 treatment

    Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Approximately 3 years

Secondary outcomes

  1. To assess the long-term efficacy of ESK-001

    Change from baseline in Psoriasis Area and Severity Index (PASI) over time

    Time frame: Approximately 3 years

  2. To assess the change in quality of life (QoL) with long-term ESK-001 administration

    Change from baseline in Dermatology Life Quality Index (DLQI) over time

    Time frame: Approximately 3 years

  3. To assess the pharmacokinetics (PK) of ESK-001 (ctrough)

    Plasma concentrations and PK parameters including steady-state trough observed plasma concentration (Ctrough) for ESK-001

    Time frame: 2 years

07

Study locations

38 sites
  • Investigator Site # 1029
    Birmingham, Alabama 35205, United States
  • Investigator Site #1001
    Phoenix, Arizona 85032, United States
  • Investigator Site # 1023
    Rogers, Arkansas 72758, United States
  • Investigator Site #1021
    Encinitas, California 92024, United States
  • Investigator Site #1018
    Los Angeles, California 90045, United States
  • Investigator Site #1007
    Santa Monica, California 90404, United States
  • Investigator Site #1002
    Sherman Oaks, California 91403, United States
  • Investigator site # 1030
    Fort Lauderdale, Florida 33308, United States
  • Investigator Site #1025
    Hialeah, Florida 33012, United States
  • Investigator site # 1028
    Miami, Florida 33175, United States
  • Investigator Site # 1013
    Tampa, Florida 33614, United States
  • Investigator Site #1035
    Macon, Georgia 31217, United States
  • Investigator Site #1043
    Sandy Springs, Georgia 30328, United States
  • Investigator Site #1005
    Rolling Meadows, Illinois 60008, United States
  • Investigator Site # 1011
    Columbus, Indiana 47201, United States
  • Investigator Site #1027
    South Bend, Indiana 46617, United States
  • Investigator SIte#1036
    Overland Park, Kansas 66210, United States
  • Investigator Site #1017
    Owensboro, Kentucky 42301, United States
  • Investigator Site #1026
    Rockville, Maryland 20850, United States
  • Investigator Site #1010
    Clarkston, Michigan 48346, United States
  • Investigator Site #1031
    New Brighton, Minnesota 55112, United States
  • Investigator Site #1033
    Norman, Oklahoma 73071, United States
  • Investigator Site #1019
    Portland, Oregon 97223, United States
  • Investigator Site #1022
    Philadelphia, Pennsylvania 19103, United States
  • Investigator Site # 1012
    Rapid City, South Dakota 57702, United States
  • Investigator Site #1015
    Houston, Texas 77056, United States
  • Investigator Site # 1006
    San Antonio, Texas 78213, United States
  • Investigator Site # 1041
    South Jordan, Utah 84095, United States
  • Investigator Site #2001
    Edmonton, Alberta T6G 1C3, Canada
  • Investigator Site # 2008
    Surrey, British Columbia V3V 0C6, Canada
  • Investigator Site #2003
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Investigator Site #2006
    London, Ontario N6H 5L5, Canada
  • Investigator Site # 2004
    Mississauga, Ontario L4Y 4C5, Canada
  • Investigator Site # 2007
    North Bay, Ontario PiB 3Z7, Canada
  • Investigator Site #2005
    Oakville, Ontario L6J 7W5, Canada
  • Investigator Site #2009
    Toronto, Ontario M3H 5Y8, Canada
  • Investigator Site # 2002
    Waterloo, Ontario N2J 1C4, Canada
  • Investigator Site # 2010
    Québec, Quebec G1V 4X7, Canada
08

References and documents

Publications

  • Papp KA, Jacobs S, Sofen H, Bukhalo M, Muscianisi E, Ma G, Lau G, Bettinger M, Rubio RG, Hitraya E, Blauvelt A; Open-Label Extension study team. Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study. J Am Acad Dermatol. 2026 Jan;94(1):187-195. doi: 10.1016/j.jaad.2025.10.005. Epub 2025 Oct 6. PubMed 41061968 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 58 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2023
First posted
Feb 22, 2023
StartActual
Jan 17, 2023
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05739435
Lead sponsor
Alumis Inc
Responsible party
Sponsor
First posted
Feb 22, 2023
Start date
Jan 17, 2023
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Envudeucitinib

Start the discussion